What Are the Chances of Getting Chlamydia If Your Partner Has It?

Over the course of a sexual partnership with someone who has chlamydia, the chances of catching it range from roughly 5% to 55%, depending on the direction of transmission and how many times you have sex. The best available estimates put the per-partnership risk at around 30–35% for transmission from a male partner to a female partner, and lower in the other direction. That single range, though, hides a lot of variation driven by anatomy, condom use, bacterial load, immune factors, and the type of sex involved.

The Per-Partnership Numbers

The most rigorous estimate of chlamydia transmission comes from a 2021 evidence synthesis that combined data from two large population-based surveys, one from the UK and one from the US. Using the British survey, the median probability of transmission over the life of a partnership was about 32% from men to women and about 21% from women to men. The American survey data produced a similar male-to-female figure of roughly 35%, but the female-to-male estimate dropped to about 5%. ¹ The wide gap between those female-to-male estimates reflects genuine uncertainty in the data, not a settled answer. What is consistent across both datasets is that male-to-female transmission is more likely than the reverse.

These numbers describe an entire partnership, meaning the cumulative risk from all unprotected sexual encounters over its duration. For any single act of vaginal intercourse, the risk is much smaller. Modeling work has estimated the per-sex-act transmission probability at around 4.5%, assuming roughly one unprotected encounter per week.² That per-act figure compounds over time: have sex ten times with an infected partner and your cumulative risk climbs well above a coin flip. The difference between a 4.5% single-encounter risk and a 30-something percent partnership risk is mostly just math and repetition.

Why Transmission Is Easier in One Direction

The asymmetry between male-to-female and female-to-male transmission is a recurring finding, and it has a straightforward anatomical explanation. The cervix provides a large area of susceptible columnar epithelial cells that chlamydia targets. During vaginal intercourse, infected semen stays in prolonged contact with those cells. For transmission in the other direction, the male urethra is the primary site of infection, and its smaller mucosal surface and shorter exposure time during sex make transmission less efficient. This same directional asymmetry appears across other bacterial sexually transmitted infections.

The practical implication is that women face a higher per-encounter risk from an infected male partner than men face from an infected female partner. But “lower risk” does not mean “low risk” over the course of a relationship. Even the more conservative female-to-male estimates mean that men whose partners have chlamydia have a meaningful chance of acquiring it if the partnership continues without treatment.

Extragenital Routes and Why They Complicate the Picture

Chlamydia is not limited to genital-to-genital transmission. The bacterium can infect the throat, rectum, and eyes in addition to the genitals and cervix. Among men who have sex with men, anorectal chlamydia is one of the most frequently detected infections at non-genital sites.³ STI prevalence studies in MSM populations have found chlamydia at rates of 7–14% depending on HIV status and PrEP use, with condomless sex roughly doubling the odds of testing positive for at least one STI.⁴

What makes extragenital chlamydia tricky is that it can spread through routes people do not always think of as risky. Mathematical modeling has shown that oral and anal sex alone cannot fully explain the observed rates of infection at multiple body sites simultaneously. Researchers found that including sequential sexual practices within the same encounter, such as oral sex followed by anal sex where saliva can carry the bacterium from the throat to the rectum, was needed to replicate real-world multisite infection patterns.⁵ A separate study confirmed that viable chlamydia can end up in the rectum even when the only reported sexual exposure was oral, likely through this kind of sequential contamination.⁶

Rimming adds another layer. A prospective cohort study found that insertive rimming nearly tripled the overall risk of chlamydia infection.⁷ The transmission probabilities quoted at the top of this article were estimated from heterosexual vaginal sex data, so they do not capture these additional routes. If your sexual repertoire includes oral, anal, or combinations of both, your actual risk could be higher than those headline figures suggest.

The Asymptomatic Problem

One of the most important factors in chlamydia transmission is that most infected people do not know they are infected. Chlamydia is frequently called a “silent” infection for good reason. Studies in high-risk populations have found that asymptomatic infections can account for the majority of detected cases, with one Ugandan study finding that all diagnosed STIs in women were asymptomatic, at a prevalence of about 6%.⁸ When people have no symptoms, they have no reason to avoid sex or seek treatment, and the infection quietly persists and spreads.

This has a direct bearing on the question of transmission odds. The per-partnership figures assume you know your partner is infected, but in practice most people do not. Screening studies in Norwegian adolescents found that about 65% of those with chlamydia rated their personal risk as “no” or “low,” and roughly half of infections were detected in that self-assured group. Women were more likely than men to underestimate their risk.⁹ So the realistic scenario for many people is not “my partner told me they have chlamydia, what are my chances?” but rather “my partner has chlamydia and neither of us knows it, so exposure continues uninterrupted.”

Bacterial Load and How Long the Infection Has Been There

Not every chlamydia infection is equally contagious. The amount of bacteria present, known as the chlamydial load, varies between individuals and over the course of an infection. People with a higher bacterial load are thought to be more likely to pass the infection to a sexual partner, consistent with what has been demonstrated for other STIs.¹⁰ Load can differ between partners even when they share the same chlamydia strain, and women tend to carry higher loads than men for certain genotypes.¹¹

Infection duration matters too, but not in the way you might expect. Chlamydia does not necessarily stick around forever. Some infections clear on their own without treatment, and this has been documented in multiple studies, particularly in women.¹² However, there is a wide range. Some infections clear quickly, while slow-clearing infections can persist for years. One modeling study estimated that infections in the slow-clearing group lasted a median of nearly three years.¹³ The same study found that infections clear more slowly in men than in women, but are less likely to establish themselves in men in the first place, which is consistent with the directional transmission asymmetry discussed earlier.

How Much Condoms Reduce the Risk

Condoms work, but they are not a perfect shield against chlamydia. Among people with known exposure to an infected partner, one study found that consistent condom users had a chlamydia rate of about 13%, compared to about 34% among inconsistent users.¹⁴ A separate analysis of people with confirmed exposure to gonorrhea or chlamydia found that consistent condom users had a combined infection rate of 30%, versus 43% among inconsistent users.¹⁵

Those numbers mean condoms cut the risk by a substantial amount, probably by more than half in well-controlled analyses, but they do not eliminate it. Part of the reason is that “consistent” use in real life still involves opportunities for skin-to-skin contact before the condom goes on, and chlamydia can infect sites that a condom does not cover, like the rectum or throat. The protection condoms offer against chlamydia is real and worth having, but it is less complete than their protection against HIV, where the barrier is more directly aligned with the route of transmission.

Individual Susceptibility Varies More Than You’d Think

Two people exposed to the same infected partner can have very different outcomes, and genetics is part of the reason. Research has identified specific genetic variants that influence how the immune system responds to chlamydia, particularly in terms of whether the infection stays localized or spreads to the upper reproductive tract. Genes involved in T-cell function, tryptophan metabolism (tryptophan is a nutrient chlamydia depends on), and the integrity of the epithelial barrier all appear to play a role.¹⁶ Additional work has linked certain immune system gene variants to chlamydia-related infertility, with identified loci involved in interferon production, fibrosis, and reproductive tract health.¹⁷ Even specific HLA alleles have been associated with susceptibility to chlamydia-related tubal damage.¹⁸

The vaginal microbiome adds another variable. Women whose vaginal bacteria are dominated by a particular species called Lactobacillus iners, as opposed to other lactobacillus species, have roughly two and a half times the odds of becoming infected with chlamydia.¹⁹ The cervicovaginal microbiome composition also influences whether chlamydia spreads from the cervix up into the uterus, which is when the real damage to fertility occurs.²⁰ None of this is actionable in the sense that you can change your HLA type or hand-pick your vaginal microbes, but it helps explain why some people seem to catch chlamydia readily while others exposed in similar circumstances do not.

The Reinfection Trap

Getting treated for chlamydia does not end the story if your partner is not treated too. Repeat infections after treatment are common, and untreated partners in ongoing relationships are a major reason why.²¹ A mathematical modeling study estimated that without partner treatment, the probability of reinfection from an untreated partner is about 19%, with a range of roughly 9–32%.²² That is not the probability per encounter; it is the expected probability of reinfection from continuing the partnership after one person is treated and the other is not.

Expedited partner therapy, where a clinician provides medication for the partner through the diagnosed patient without requiring the partner to come in for their own visit, was developed to address this problem. It consistently increases the rate at which partners actually get treated.²³ Whether it translates into lower reinfection rates in practice is less clear-cut. A study of female adolescents found that reinfection rates were somewhat lower among those who accepted expedited partner therapy compared to those who did not, but the differences were not statistically significant.²⁴ The concept is sound, but real-world effectiveness depends on whether the partner actually takes the medication and whether there are other untreated sexual contacts in the picture.

Doxycycline as Post-Exposure Prevention

A newer strategy that has gained attention is doxycycline post-exposure prophylaxis, sometimes called doxy-PEP. The idea is to take a dose of the antibiotic doxycycline within 72 hours after a potential exposure. Four randomized controlled trials and several real-world analyses have consistently shown that doxy-PEP reduces chlamydia infections among men who have sex with men.²⁵ The evidence is strong enough for MSM that some clinical guidelines now include it as an option, particularly for people at high risk of repeat infections.

The picture is less complete for cisgender women. The biology is different because doxycycline concentrations in vaginal tissue may not reach the same levels as in rectal or urethral tissue, and trials in women have been limited. For now, doxy-PEP is primarily discussed in the context of MSM and transgender women, with ongoing research to determine whether it can benefit a broader population. It also raises legitimate concerns about antibiotic resistance, since widespread prophylactic antibiotic use could pressure bacteria to evolve resistance over time.

Co-Infections With Other STIs

Chlamydia rarely travels alone. People who test positive for one STI are at elevated risk of having another, either because the same exposure transmitted both or because the behavioral and biological factors overlap. Among women infected with gonorrhea in the US, the rate of concurrent chlamydia infection was highest in teenagers, reaching 46% in those aged 15 to 19.²⁶ This is one reason clinical guidelines recommend testing for chlamydia whenever gonorrhea is found, and vice versa. The presence of chlamydia can also increase susceptibility to HIV by disrupting mucosal barriers, which makes treating chlamydia a secondary HIV prevention strategy in high-prevalence settings.

Transmission During Childbirth

Chlamydia can also pass from mother to infant during delivery, which is a different kind of “partner” transmission but one that matters. After vaginal birth, chlamydia was isolated from nearly half of infants born to infected mothers in a study that examined cephalic (head-first) presentations.²⁷ The resulting infections in newborns most commonly affect the eyes, causing conjunctivitis, or the lungs, causing pneumonia. Prenatal chlamydia screening and treatment are standard in most healthcare systems specifically to prevent this route of transmission.